Company / Financials
Annovis Bio, Inc. Financials
FY2020-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableRevenue
$0
FY2025
Net Income
-$28.9M
FY2025 · +48.7% YoY
Profit Margin
-
FY2025 · net income / revenue
ROE
-171.2%
FY2025 · return on equity
Total Assets
$21.1M
FY2025
Total Debt
-
FY2025
Equity
$16.9M
FY2025
ROA
-136.9%
FY2025 · return on assets
Statement paths
Financial highlights
Key Data Points
- Low Piotroski F-Score: 2/9 (multiple financial health concerns)
- Altman Z-Score -9.28 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Metric history
Revenue HistoryTotal revenue from operations$0Net Income HistoryProfit after all expenses and taxes-$28.9M+48.7% YoYOperating Income HistoryProfit from core business operations before interest and taxes-$29.7M+34.1% YoYSG&A Expense HistorySelling, general, and administrative expenses$4.5M-28.3% YoYR&D Expense HistoryResearch and development spending$25.2M-35.0% YoYIncome Tax HistoryTotal income tax expense$0EPS (Basic) HistoryBasic earnings per share-$2.02+67.6% YoYEPS (Diluted) HistoryDiluted earnings per share including stock options and convertibles-$2.31+62.9% YoYShares Outstanding HistoryWeighted average diluted shares outstanding14.1M+34.4% YoYTotal Assets HistoryTotal value of all assets owned$21.1M+51.4% YoY